UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical Significance of Microbial Infection and Adaptation in Cystic Fibrosis

Clinical Microbiology Reviews, 2011-01, Vol.24 (1), p.29-70

2011

Volltextzugriff (PDF)

Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation

The Journal of pediatrics, 2017-02, Vol.181, p.S4-S15.e1

2017

Volltextzugriff (PDF)

Airway microbiota across age and disease spectrum in cystic fibrosis

The European respiratory journal, 2017-11, Vol.50 (5), p.1700832-1700832

2017

Volltextzugriff (PDF)

Soft, skin-interfaced sweat stickers for cystic fibrosis diagnosis and management

Science translational medicine, 2021-03, Vol.13 (587)

2021

Volltextzugriff (PDF)

A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial

The lancet respiratory medicine, 2014-07, Vol.2 (7), p.527-538

2014

Volltextzugriff (PDF)

Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial

The lancet respiratory medicine, 2015-07, Vol.3 (7), p.524-533

2015

Volltextzugriff (PDF)

Diagnosis of Cystic Fibrosis in Screened Populations

The Journal of pediatrics, 2017-02, Vol.181, p.S33-S44.e2

2017

Volltextzugriff (PDF)

Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype

Pediatric pulmonology, 2021-06, Vol.56 (6), p.1496-1503

2021

Volltextzugriff (PDF)

Editor's response to “An oversight regarding the club cell?”

Pediatric pulmonology, 2022-09, Vol.57 (9), p.2263-2263

McColley, Susanna A.

2022

Volltextzugriff (PDF)

Pancreatic Enzyme Replacement Therapy Dosing and Nutritional Outcomes in Children with Cystic Fibrosis

The Journal of pediatrics, 2014-05, Vol.164 (5), p.1110-1115.e1

2014

Volltextzugriff (PDF)

Association of Socioeconomic Status with the Use of Chronic Therapies and Healthcare Utilization in Children with Cystic Fibrosis

The Journal of pediatrics, 2009-11, Vol.155 (5), p.634-639.e4

2009

Volltextzugriff (PDF)

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR

The New England journal of medicine, 2015-07, Vol.373 (3), p.220-231

2015

Volltextzugriff (PDF)

Newborn Screening for Cystic Fibrosis: A Qualitative Study of Successes and Challenges from Universal Screening in the United States

International journal of neonatal screening, 2022-06, Vol.8 (3), p.38

2022

Volltextzugriff (PDF)

Barriers to and solutions for representative inclusion across the lifespan and in life course research: The need for structural competency highlighted by the COVID-19 pandemic

Journal of clinical and translational science, 2023, Vol.7 (1), p.e38-e38, Article e38

2023

Volltextzugriff (PDF)

Predicting the course of nutrition and lung disease in infants and children with cystic fibrosis

Journal of cystic fibrosis, 2020-11, Vol.19 (6), p.847-849

McColley, Susanna A.

2020

Volltextzugriff (PDF)

A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele

American journal of respiratory and critical care medicine, 2021-06, Vol.203 (12), p.1522-1532

2021

Volltextzugriff (PDF)

Anti-racist strategies for clinical and translational research: Design, implementation, and lessons learned from a new course

Journal of clinical and translational science, 2023, Vol.7 (1), p.e26, Article e26

2023

Volltextzugriff (PDF)

Barriers and facilitators to recruitment of underrepresented research participants: Perspectives of clinical research coordinators

Journal of clinical and translational science, 2023, Vol.7 (1), p.e193-e193, Article e193

2023

Volltextzugriff (PDF)

Transition to adulthood and adult health care for patients with sickle cell disease or cystic fibrosis: Current practices and research priorities

Journal of clinical and translational science, 2018-10, Vol.2 (5), p.334-342

2018

Volltextzugriff (PDF)

Are children with chronic illnesses requiring dietary therapy at risk for disordered eating or eating disorders? A systematic review

The International journal of eating disorders, 2018-03, Vol.51 (3), p.187-213

2018

Volltextzugriff (PDF)

The Need for Quality Improvement in Sweat Testing Infants after Newborn Screening for Cystic Fibrosis

The Journal of pediatrics, 2010-12, Vol.157 (6), p.1035-1037

2010

Volltextzugriff (PDF)

Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One F508del Allele

American journal of respiratory and critical care medicine, 2023-07, Vol.208 (1), p.59-67

2023

Volltextzugriff (PDF)

Detection of disease‐causing CFTR variants in state newborn screening programs

Pediatric pulmonology, 2023-02, Vol.58 (2), p.465-474

2023

Volltextzugriff (PDF)

Cystic fibrosis year in review 2019: Section 2 pulmonary disease and infections

Pediatric pulmonology, 2023-03, Vol.58 (3), p.672-682

2023

Volltextzugriff (PDF)

In response to “who are the 10%? – Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies”

Respiratory medicine, 2022-10, Vol.202, p.106953-106953, Article 106953

2022

Volltextzugriff (PDF)

1 – 25 von 151

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(140)
Mit Volltextzugriff
(124)

Publikationsform

Sprache

Englisch
(151)

Erscheinungsjahr

n.n

Thema

Science & Technology
(129)
Life Sciences & Biomedicine
(128)
Humans
(104)
Respiratory System
(73)
Cystic Fibrosis
(71)
Pediatrics
(66)
Child
(61)
Female
(51)
Male
(51)
Adolescent
(40)
Biological And Medical Sciences
(33)
Medical Sciences
(33)
Child, Preschool
(32)
Cystic Fibrosis - Drug Therapy
(32)
Cystic Fibrosis - Genetics
(28)
Cystic Fibrosis Transmembrane Conductance Regulator - Genetics
(27)
General & Internal Medicine
(27)
Infant
(27)
Critical Care Medicine
(25)
Cystic Fibrosis - Diagnosis
(25)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical Significance of Microbial Infection and Adaptation in Cystic Fibrosis

Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation

Airway microbiota across age and disease spectrum in cystic fibrosis

Soft, skin-interfaced sweat stickers for cystic fibrosis diagnosis and management

A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial

Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial

Diagnosis of Cystic Fibrosis in Screened Populations

Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype

Editor's response to “An oversight regarding the club cell?”

Pancreatic Enzyme Replacement Therapy Dosing and Nutritional Outcomes in Children with Cystic Fibrosis

Association of Socioeconomic Status with the Use of Chronic Therapies and Healthcare Utilization in Children with Cystic Fibrosis

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR

Newborn Screening for Cystic Fibrosis: A Qualitative Study of Successes and Challenges from Universal Screening in the United States

Barriers to and solutions for representative inclusion across the lifespan and in life course research: The need for structural competency highlighted by the COVID-19 pandemic

Predicting the course of nutrition and lung disease in infants and children with cystic fibrosis

A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele

Anti-racist strategies for clinical and translational research: Design, implementation, and lessons learned from a new course

Barriers and facilitators to recruitment of underrepresented research participants: Perspectives of clinical research coordinators

Transition to adulthood and adult health care for patients with sickle cell disease or cystic fibrosis: Current practices and research priorities

Are children with chronic illnesses requiring dietary therapy at risk for disordered eating or eating disorders? A systematic review

The Need for Quality Improvement in Sweat Testing Infants after Newborn Screening for Cystic Fibrosis

Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One F508del Allele

Detection of disease‐causing CFTR variants in state newborn screening programs

Cystic fibrosis year in review 2019: Section 2 pulmonary disease and infections

In response to “who are the 10%? – Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies”

Suchergebnisse filtern